GEMP Gemphire Therapeutics Inc gains 30% Sep 25, 2018

Posted By: Rajesh Srivastava - Tuesday, September 25, 2018

Share

& Comment

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.http://www.priceseries.com/trade/GEMP-Gemphire-Therapeutics-Inc-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2018090520180925.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.